Hepion Pharmaceuticals (HEPA)
(Delayed Data from NSDQ)
$2.13 USD
+0.09 (4.41%)
Updated Apr 17, 2024 03:59 PM ET
After-Market: $2.13 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
Hepion Pharmaceuticals, Inc. [HEPA]
Reports for Purchase
Showing records 1 - 20 ( 52 total )
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
AMBITION trial shows positive biomarker data
Provider: Edison Investment Research Limited
Analyst: Research Department
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
First data on liver enzymes encouraging
Provider: Edison Investment Research Limited
Analyst: CALLOWAY N
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Recapitalizing Financing Completed - Lowering Price Target
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Final Program for Our Fourth Annual Virtual NASH Investor Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We are updating coverage of our Healthcare sector to better allocate our research resources in
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Most Explored Anti-Fibrotic in NASH, Transferring Coverage
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Phase I clinical trial nearing completion
Provider: Edison Investment Research Limited
Analyst: CALLOWAY N